Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 202 participants.

Also called NCT06676696

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 202 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06676696
  • EU CT 2023-506879-98-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06676696. Randomized; no masking; primary purpose treatment. Start 2024-01-22 (actual); primary completion 2028-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
Condition
Renal Failure , Chronic
Condition
Graft Failure
Condition
Graft Rejection
Condition
Allograft
Condition
Renal Failure Chronic Requiring Dialysis
Intervention (Drug)
Continue low dose calcineurin inhibitor (CNI)
Intervention (Drug)
Calcineurin inhibitor withdrawal at 6 months
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute (class: other)

Record details

Record id
cardio:ct-nct06676696
Content hash
43ad773a1fc21c2c20b285289b729ea89836b8bcaf5857c4df14c85c926a8262